Peanut Allergy clinical trials at UCLA
3 in progress, 1 open to eligible people
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
open to eligible people ages 4-65
This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
Los Angeles, California and other locations
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Sorry, in progress, not accepting new patients
Open-label, follow-up study for subjects who completed the EPITOPE study.
Los Angeles, California and other locations
Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Sorry, in progress, not accepting new patients
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Los Angeles, California and other locations
Our lead scientists for Peanut Allergy research studies include Maria I. Garcia-Lloret, MD.
Last updated: